Deglycyrrhizinated licorice, or DGL, has been used clinically for decades, primarily for the treatment of peptic ulcers. Licorice has been shown to inhibit several inflammatory enzymes, including both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX), decreasing the production of several potent inflammatory compounds, including prostaglandin E2, thromboxane B2, and leukotriene B4. Importantly, this inhibition is not due to glycyrrhizic acid, the component of licorice which has been removed in DGL, and which is associated with mineralocorticoid excess and hypertension. Another component of licorice, glabridin, has been shown to prevent lipopolysaccharide (LPS) induced production of inflammatory compounds, including nitric oxide and interleukin-1 beta, whereas glycyrrhizic acid has no effect.
Clinically, DGL has been shown to have comparable efficacy to cimetidine for both the healing and prevention of ulcer recurrences. Additionally, extracts of licorice have been shown to inhibit the adhesion of H. pylori to gastric mucosa, as well as the growth of antibiotic resistant strains, suggesting multiple mechanisms of action for its anti-ulcer benefit.The use of chewable tablets appears necessary for DGL’s efficacy, as it allows for distribution and absorption by the gastric mucosa.
Deglycyrrhizinated甘草，或DGL，已在临床上使用了数十年，主要用于治疗消化性溃疡.甘草已被证明可抑制几种炎症酶，包括环氧合酶-2（COX-2）和5-脂氧合酶（5-LOX） ），减少几种强效炎症化合物的产生，包括前列腺素E2，血栓素B2和白三烯B4。重要的是，这种抑制作用不是甘草酸，甘草的成分已经在DGL中被去除，并且与盐皮质激素过量和高血压相关。甘草的另一种成分，glabridin，已被证明可以预防脂多糖（LPS）诱导产生炎症化合物，包括一氧化氮和白细胞介素-1β，而甘草酸没有效果。 临床上，DGL已被证明具有与西咪替丁相似的治疗和预防溃疡复发的功效. 此外，甘草提取物已被证明可抑制幽门螺杆菌与胃粘膜的粘附，以及抗生素的生长。耐药菌株，提示其抗溃疡作用的多种作用机制。对于DGL的功效，咀嚼片的使用似乎是必要的，因为它允许胃粘膜的分布和吸收。